Logo image of CYTK

CYTOKINETICS INC (CYTK) Stock Fundamental Analysis

NASDAQ:CYTK - Nasdaq - US23282W6057 - Common Stock - Currency: USD

40.43  +0.1 (+0.25%)

After market: 40.43 0 (0%)

Fundamental Rating

2

CYTK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTK have multiple concerns. CYTK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CYTK has reported negative net income.
In the past year CYTK has reported a negative cash flow from operations.
CYTK had negative earnings in each of the past 5 years.
CYTK had negative operating cash flow in 4 of the past 5 years.
CYTK Yearly Net Income VS EBIT VS OCF VS FCFCYTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

CYTK has a Return On Assets of -42.06%. This is comparable to the rest of the industry: CYTK outperforms 53.79% of its industry peers.
Industry RankSector Rank
ROA -42.06%
ROE N/A
ROIC N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTK Yearly ROA, ROE, ROICCYTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

CYTK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTK Yearly Profit, Operating, Gross MarginsCYTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYTK has more shares outstanding than it did 1 year ago.
CYTK has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CYTK has an improved debt to assets ratio.
CYTK Yearly Shares OutstandingCYTK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CYTK Yearly Total Debt VS Total AssetsCYTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

Based on the Altman-Z score of -1.27, we must say that CYTK is in the distress zone and has some risk of bankruptcy.
CYTK has a Altman-Z score of -1.27. This is comparable to the rest of the industry: CYTK outperforms 58.55% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.27
ROIC/WACCN/A
WACC9.93%
CYTK Yearly LT Debt VS Equity VS FCFCYTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

CYTK has a Current Ratio of 6.17. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.17, CYTK is in the better half of the industry, outperforming 65.08% of the companies in the same industry.
CYTK has a Quick Ratio of 6.17. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.17, CYTK is doing good in the industry, outperforming 65.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.17
Quick Ratio 6.17
CYTK Yearly Current Assets VS Current LiabilitesCYTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

CYTK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.49%.
CYTK shows a strong growth in Revenue. In the last year, the Revenue has grown by 145.27%.
The Revenue has been decreasing by -7.24% on average over the past years.
EPS 1Y (TTM)3.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
Revenue 1Y (TTM)145.27%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%912.38%

3.2 Future

Based on estimates for the next years, CYTK will show a very strong growth in Earnings Per Share. The EPS will grow by 21.77% on average per year.
CYTK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 246.02% yearly.
EPS Next Y-10.94%
EPS Next 2Y4.5%
EPS Next 3Y15.11%
EPS Next 5Y21.77%
Revenue Next Year775.08%
Revenue Next 2Y708.49%
Revenue Next 3Y434.15%
Revenue Next 5Y246.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CYTK Yearly Revenue VS EstimatesCYTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CYTK Yearly EPS VS EstimatesCYTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CYTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTK Price Earnings VS Forward Price EarningsCYTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTK Per share dataCYTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as CYTK's earnings are expected to grow with 15.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.5%
EPS Next 3Y15.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYTK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOKINETICS INC

NASDAQ:CYTK (4/25/2025, 8:00:00 PM)

After market: 40.43 0 (0%)

40.43

+0.1 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners112.72%
Inst Owner Change0.33%
Ins Owners0.44%
Ins Owner Change2.4%
Market Cap4.82B
Analysts82.22
Price Target80.26 (98.52%)
Short Float %12.38%
Short Ratio7.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.19%
Min EPS beat(2)-6.82%
Max EPS beat(2)-3.56%
EPS beat(4)0
Avg EPS beat(4)-11.54%
Min EPS beat(4)-21.59%
Max EPS beat(4)-3.56%
EPS beat(8)0
Avg EPS beat(8)-23.91%
EPS beat(12)1
Avg EPS beat(12)-13.71%
EPS beat(16)2
Avg EPS beat(16)-10.36%
Revenue beat(2)1
Avg Revenue beat(2)395.54%
Min Revenue beat(2)-62.02%
Max Revenue beat(2)853.1%
Revenue beat(4)1
Avg Revenue beat(4)177.14%
Min Revenue beat(4)-73.51%
Max Revenue beat(4)853.1%
Revenue beat(8)2
Avg Revenue beat(8)69.59%
Revenue beat(12)3
Avg Revenue beat(12)224.39%
Revenue beat(16)4
Avg Revenue beat(16)212.82%
PT rev (1m)-1.77%
PT rev (3m)-5.34%
EPS NQ rev (1m)0.14%
EPS NQ rev (3m)-8.02%
EPS NY rev (1m)0.28%
EPS NY rev (3m)-6.44%
Revenue NQ rev (1m)-5.03%
Revenue NQ rev (3m)140.59%
Revenue NY rev (1m)-43.59%
Revenue NY rev (3m)-45.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 260.91
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.26
EYN/A
EPS(NY)-5.84
Fwd EYN/A
FCF(TTM)-3.35
FCFYN/A
OCF(TTM)-3.32
OCFYN/A
SpS0.15
BVpS-1.14
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.98%
Cap/Sales 21.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.17
Quick Ratio 6.17
Altman-Z -1.27
F-Score6
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)82.69%
Cap/Depr(5y)599.06%
Cap/Sales(3y)17.31%
Cap/Sales(5y)28.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
EPS Next Y-10.94%
EPS Next 2Y4.5%
EPS Next 3Y15.11%
EPS Next 5Y21.77%
Revenue 1Y (TTM)145.27%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%912.38%
Revenue Next Year775.08%
Revenue Next 2Y708.49%
Revenue Next 3Y434.15%
Revenue Next 5Y246.02%
EBIT growth 1Y-8.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.2%
EBIT Next 3Y9.78%
EBIT Next 5Y24.98%
FCF growth 1Y3.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.45%
OCF growth 3YN/A
OCF growth 5YN/A